Ocular Therapeutix Inc

Research Ocular Therapeutix Inc (OCUL) on Bullrun: market cap USD 2.17B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerOCUL
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.17B
• Financial periodFY2025
• RevenueUSD 51.95M
• Revenue growth-18.5%
• Net income-USD 265.94M
• Free cash flow-USD 216.89M
• Gross margin87.3%

Valuation Snapshot

latest market cap is USD 2.17B.

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Frequently asked questions

What is Ocular Therapeutix Inc's market cap?

Ocular Therapeutix Inc's market capitalization is USD 2.17B.

What does Ocular Therapeutix Inc do?

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.